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Abstract
Background: Neurodevelopmental brain disorders such as schizophrenia, autism and attention deficit hyperactivity
disorder are complex disorders with heterogeneous etiologies. Schizophrenia and autism are difficult to treat and
often cause major individual suffering largely owing to our limited understanding of the disease biology. Thus our
understanding of the biological pathogenesis needs to be substantiated to enable development of more targeted
treatment options with improved efficacy. Insights into the pre-morbid disease dynamics, the morbid condition and
the underlying biological disease mechanisms may come from studies of subjects with homogenous etiologies.
Breakthroughs in psychiatric genetics have shown that several genetic anomalies predispose for neurodevelopmental
brain disorders. We have established a Danish research initiative to study the common microdeletion at chromosome
22q11.2, which is one of the genetic anomalies that confer high risk of schizophrenia, autism and attention deficit
hyperactivity disorder.
Methods/design: The study applies a “cause-to-outcome” strategy to identify pre-morbid pathogenesis and
underlying biological disease mechanisms of psychosis and secondarily the morbid condition of autism and attention
deficit hyperactivity disorder. We use a population based epidemiological design to inform on disease prevalence,
environmental risk factors and familial disposition for mental health disorders and a case control study design to map
the functional effects across behavioral and neurophysiological traits of the 22q11 deletion in a recruited sample of
Danish individuals.
Discussion: Identification of predictive pre-morbid clinical, cognitive, functional and structural brain alterations in
22q11 deletion carriers may alter current clinical practice from symptomatic therapy of manifest mental illness into
early intervention strategies, which may also be applicable to at risk subjects without known etiology. Hopefully new
insights into the biological disease mechanisms, which are mandatory for novel drug developments, can improve the
outcome of the pharmacological interventions in psychiatry.
Background
Neurodevelopmental brain disorders, such as schizophre-
nia, autism and attention deficit hyperactivity disorder
(ADHD) are major causes of life-long suffering to the indi-
vidual and impose huge costs to society. Emerging evidence
within the psychosis research field suggest that early inter-
vention may improve treatment outcome and even reduce
the disease transition rate [1], yet treatment options are
poor at best. This is largely due to the insufficient under-
standing of the early prodromal traits and the disease
etiology and pathology.
Recent human genetic studies have reported that dele-
tions or duplications of chromosomal regions termed copy
number variants can cause a wide range of neurodevelop-
mental brain disorders [2–14]. An emerging feature of
these findings is that a single disorder can be caused by
different copy number variants (i.e. genetic heterogeneity)
and that a single copy number variant can confer risk of
different disorders (i.e. pleiotropy). The discoveries have
increased the understanding of developmental mental
disorders as arising from complex patterns of etiologies
and pathologies that are not confined to the boundaries of
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the purely conventional diagnostic systems of current
psychiatry. Thus, diagnostic homogeneity is no guarantee
for uniform pathology and even less so, for shared etiology.
We believe that the findings of genetic high risk factors
for mental disorders motivate clinical “cause to outcome”
studies, focused on subjects who share a common genetic
risk factor for whom the observed symptomatology and
underlying biological perturbations can be ascribed to that
particular risk factor.
The 22q11.2 microdeletion on the long arm of chromo-
some 22 is the most common copy number variant in
humans, with an estimated prevalence of approximately
1:2000 to 1:4000 live births [15–17]. The majority (approxi-
mately 90 %) of microdeletions that have been detected at
chromosome 22q11.2 are 3 megabases in size. A 1.5 mega-
bases deletion nested within the common 3 megabase
region is less frequently observed [18] and rare atypical
microdeletions of different sizes have also been described
[19–21]. The common deletion was recognized early on as
the cause of DiGeorge Syndrome and velo-cardio-facial
syndrome (and recently the 22q11 deletion syndrome)
encompassing multiple somatic conditions, including con-
genital heart disease, velopharyngeal insufficiency, immune
deficiency, facial dysmorphism and intellectual disability
[22–24].
Over the past decades it has become increasingly
clear that the common 22q11 deletion also confers very
high risk of neurodevelopmental brain disorders, in-
cluding schizophrenia, autism, and ADHD. Studies of
patients with schizophrenia find that carriers of the de-
letion account for approximately 1–2 % of the sporadic
cases [25]. The International Consortium on Brain and
Behavior in 22q11.2 has recently provided the best
estimates of disease prevalence so far. Their data show
that schizophrenia (in broad sense) affects 24 % of the
22q11 deletion carriers during adolescents and 41 % in
adulthood. Among the children and adolescents 12 and
27 %, respectively, have been diagnosed within the aut-
ism spectrum disorders, while a diagnosis of ADHD
has been given to 37 % of the affected children, 24 % of
the adolescents and 16 % of the 22q11 deletion carriers
who are in their early adulthood [26].
Widespread cognitive deficits and neuroanatomical
and neurophysiological alterations are prevalent in 22q11
deletion carriers. The cognitive impairments span across
several domains of neurocognitive functions including
intelligence, spatial and verbal memory, working memory,
problem solving and planning, attention, processing speed,
impulsivity, to social cognitive functions (i.e. emotion rec-
ognition and Theory of Mind), and social behavior [27–29].
The neuroanatomical phenotype include delayed brain
maturation during adolescence [30], and regional and
whole brain alterations such as significant reductions in
regional brain volume, cortical thickness, gyrification,
and diminished grey - and white matter density, as well as
alterations in functional connectivity in adulthood [31–33].
Furthermore, 22q11 deletion carriers have shown neuro-
physiological alterations during resting-state electroenceph-
alography (EEG) in the expression of functional microstates
defined by few recurrent and dominant classes of scalp top-
ographies, which suggests that the basic resting state condi-
tion in 22q11 deviates from the one reported in control
subjects [34]. Also reduced processing abilities in response
to auditory mismatch negativity (MMN) stimuli have been
reported [35].
Longitudinal studies in 22q11 deletion carriers have pri-
marily focused on psychosis outcome and have outlined
several indicators of increased risk of transition to psych-
osis, including low verbal IQ [36, 37], poor theory of mind
abilities and reduced processing speed [27]. Regional reduc-
tions in grey matter volume of the temporal cortex [38]
and right medial orbitofrontal cortex [39] have been associ-
ated with positive symptom severity. Reduced functional
activation of intraparietal sulcus during working memory
testing have been associated with more severe clinical
symptoms of unusual thought content and delusional ideas
in 22q11 deletion carriers [40]. Sinderberry and collabora-
tors merged multiple data across cognitive functions and
brain anatomy as well as facial morphology and were able
to identify two subgroups of 22q11 carriers that were not
defined by clinical diagnostic criteria [41]. The diverging
phenotype sub-groups may reflect different developmental
trajectories but are not sufficiently specific in their ability to
identify subjects at risk of mental disorders. Hence, they
cannot be implemented in early intervention strategies.
Rationale
Prompted by these findings, we have established the
National Danish 22q11 Research Initiative to extend the
existing knowledge of the 22q11 deletion as an at-risk
model for neurodevelopmental disorders. The rational for
doing focused studies on one genetic risk factor such as the
22q11 deletion stems from the etiological homogeneity i.e.
all cases are affected by a the same high impact risk factor.
The assumption is that the pathogenesis and pathology
caused by one risk factor is less heterogeneous than within
diagnostic group of mental disorder in general where mul-
tiple etiologies are at play. Therefore, the power to detect
significant effects of the 22q11 deletion on symptomatology
is likely to be higher compared to traditional high-risk stud-
ies focusing on a single diagnosis. Thus, we can track the
path from the 22q11 deletion across biological and func-
tional modalities to the pathophysiological outcomes and
clinical presentations.
Aim
The overall objective is the identification of a multi-dimen-
sional model, which spans cognitive, neuroanatomical, and
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neurophysiological domains as wells as environmental ex-
posures and family disposition and is predictive of the
pathology currently defined by the diagnostic criteria for
schizophrenia, autism or ADHD.
Methods
Overall design
In order to achieve our overall objective, we are applying
two overall complementary approaches: a population based
registers study and a functional and structural study.
We adopt a population based epidemiological design to
(a) inform on the incidence rate of developmental mental
disorders in a nation-wide population of 22q11 deletion
carriers in Denmark, (b) map family disposition of mental
disorders, environmental factors and prenatal stressors
(e.g. infections and fatigue) and address the impact of
these factors on disease outcomes, and (c) to follow the
trajectories in disease propagation over time.
The functional and structural studies are based on a
recruited sample of 22q11 deletion carriers. In these studies
we use (a) a cross-sectional case–control study design to
identify genuine imprints of the 22q11 deletion itself, (b) a
case-only design nested within the cross-sectional setup to
uncover correlations between cognitive and neuro- ana-
tomical and -physiological measurements and levels of
psychopathology, (c) a family design to investigate the
familial resembles of inherited forms of the 22q11 deletion
to discover additional risk factors/biomarkers.
Epidemiological register based sub-studies
Incidence rates of disease and the impact on disease out-
comes of early life events and environmental exposures are
difficult to estimate from observational studies in humans.
We apply epidemiological survival analyses to mine the
wealth of health information in the Danish registries to
address these issues for a nation-wide sample of 22q11
deletion carriers compared to the Danish population as a
whole.
In Denmark all citizens are registered with a unique civil
registration number given at birth or upon immigration.
The civil registration number is registered in the Danish
civil registry, which holds information on all persons who
have lived in Denmark since April 2nd 1968. The Danish
health registries automatically obtain records on all clinical
discharge diagnoses defined according to the International
Classification of Diseases (ICD) system and the information
is linked to the civil registration number. Thus the national
health registries in Denmark hold information on the
disease propensity of the Danish population including in-
formation on socioeconomic factors, family history, and
urbanization etc.
The epidemiological studies utilize information obtained
from the National Danish Health Registries including the
Danish Civil Registration System, the Danish National
Patient Registry, the Danish Psychiatric Central Register
and the Danish Cytogenetic Central Register.
The diagnostic information in the Danish health registries
refers to the ICD-8 protocol until 1994 whereas ICD-10
criteria have been applied from January 1st 1994 to date.
The Psychiatric Central Register includes information on
all psychiatric inpatient facilities since April 1, 1969 and in
addition for outpatient facilities since 1995. The Danish
Cytogenetic Central Register holds information on all
Danish subjects who have been referred for clinical genetic
testing on clinical indication and have been tested positive
for a genetic anomaly [42]. Clinical genetic testing for
deletions within the chromosome 22q11.2 region was im-
plemented in Denmark in 1994. The genetic testing is solely
performed on clinical indication and is not mandatory. The
reporting of information to Danish Cytogenetic Central
Registry is self-imposed by all departments performing
clinical genetic tests in Denmark, and the registry is admin-
istered by representatives from these departments.
Subjects
The study population contains all Danish citizens born in
1954 to present. A total number of 244 Danish citizens
(125 males and 119 females) are recorded in Danish
Cytogenetic Central Register as 22q11 deletion carriers.
This group of known Danish 22q11 carriers represents
those that have been referred for genetic testing based on
some clinical indication and have consent to be tested.
The birth year distribution of the known Danish 22q11
carriers is shown in red in Fig. 1. The majority (60 %) of
the known 22q11 deletion carries have been tested posi-
tive for the 22q11 deletion before their 6th years birthday
and the median age of a positive genetic test result is
5 years (age range 0–45 years).
Inclusion criteria
All Danish citizens born in Denmark after 1954 or later
who have references to both parents in the Danish civil
register.
Exclusion criteria
Danish citizens not born in Denmark or who have migrated
out of the country or who do not have references to both
parents in the Danish civil register.
Data retrieval
For each person, who fullfills the inclusion criteria, the
first psychiatric diagnosis (e.g. schizophrenia) is derived
from Danish Psychiatric Central Register and the date for
a positive 22q11 deletion test result is obtained from the
Cytogenetic register. Information on age, gender, birth-
place, familial disposition and somatic diagnoses are re-
trieved from the Danish National Patient Registry. We will
follow the cohort from a given age (where the ‘at risk’ for
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developing a given mental disorder is present), until the
date of their first diagnosis for this given disorder, the date
of death, the date of emigration/disappearance or 1 January
2015, whichever comes first. We will use survival analyses
(i.e. Poisson regressions), with the logarithm of person-
years as an offset variable. Incidence rates of the given dis-
order will be calculated for a relevant number of categories
(age groups, gender, paternal and maternal age etc.). Access
to the registry data has been provided and an initial study
cohort has been assembled. The case–control status of the
subjects will derivate for the down stream analyses accord-
ing to the diagnosis under investigation (i.e. schizophrenia,
autism, etc.).
Functional studies in a case–control sample
We combined in vivo neuroimaging and dimensional
behavioral testing to chart the biological mechanisms of
22q11 deletion. Electroencephalography (EEG) and magnetic
resonance imaging (MRI) are used to measure human brain
function and structure in vivo. Cognitive tests and psychi-
atric assessments are employed to provide measures of
phenotypic manifestations on quantitative and qualitative
scales.
The cognitive test protocol is enriched with tests, which
assess neuro- and social cognitive functions that have previ-
ously been associated with 22q11 carriers [28, 29] as these
impairments are also prevailing in idiopathic schizophre-
nia [25, 43], autism [44] or ADHD [45–47]. The specific
tests are listed in Table 1. Furthermore, we use auditory
mismatch negativity (MMN) paradigms in both EEG and
fMRI investigations as these reveal commonly reported
schizophrenia response deficiencies [48–50]. The MMN
paradigm probes the brain response to a sudden sensory
change, commonly tested in the auditory domain and is
explained in more detail below. By applying a MMN para-
digm during EEG and fMRI, we can capture specific brain
responses to distinct auditory changes on a high temporal
and spatial scale.
In addition, information from the national health registries
in Denmark will be used to assess familial load of mental
health issues, socio-economic and environmental risk factors
and to follow the disease trajectory for each individual over
time. We use an age limit of 12 years for enrollment to en-
sure that the children are able to comply with the entire
examination.
Recruitment
The recruitment for the functional studies has been
finalized. The 22q11 deletion carriers were primarily re-
cruited from Department of Pediatrics, Aarhus University
Hospital and Department of Clinical Genetics, Copenhagen
University Hospital that are the core sites in Denmark,
which provide general overall supervision, care and treat-
ment (if necessary) of 22q11 deletion carriers in Denmark.
Cases were initially contacted when they had appointments
at the hospital departments, or by letter and a follow-up
telephone call. In addition, 22q11 deletion carriers were
recruited through postings at family meetings held by the
Danish National 22q11DS Association. None were re-
cruited from psychiatric departments or any other subspe-
cialty clinics.
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
<
 1
98
0
19
80
19
82
19
84
19
86
19
88
19
90
19
92
19
94
19
96
19
98
20
00
20
02
20
04
20
06
20
08
20
10
Birth year
N
um
be
r 
of
 2
2q
11
 d
el
et
io
n 
ca
rr
ie
rs
Fig. 1 Birth year distribution of all known Danish carriers of the chromosome 22q11.2 deletion and a recruited sub-sample of 44 individuals. Figure subscript.
The number of known carriers of the 22q11 deletion born each year is depicted in red while the distribution of the recruited sub-sample is shown in blue
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Table 1 The behavioral and cognitive test battery
Interview, test and
questionnaires
Test outcome Test tool References
Psychiatric interviews
MINI/MINI-KID Psychiatric research diagnoses Mini International Neuropsychiatric
Interview Danish version 5.0.0 / Mini
International Neuropsychiatric Interview
for Children and Adolescents version 6.0
[53, 54, 73]
SIPS Psychotic and prodromal symptoms Structured Interview for Prodromal
Syndromes
[55, 74]
Cognitive abilities
RIST General intelligence The Reynolds Intellectual Screening Test [56]
Coding test Processing speed Wechsler Intelligence Scale 4th ed. [57, 58]
Letter-number sequencing
test
Verbal working memory Wechsler Intelligence Scale 4th ed. [57, 58]
Spatial Working Memory Spatial working memory CANTABa (SWM) www.cambridgecognition.com/
tests/working-memory-swm
Intra-Extra Dimensional
set shift
Attentional set formation, maintenance,
flexibility of attention
CANTABa (IED) www.cambridgecognition.com/
tests/intra-extra-dimensional-
set-shift-ied
Reaction Time Reaction time and motor speed CANTABa (RTI) www.cambridgecognition.com/
tests/reaction-time-rti
Emotion Recognition Task Emotional recognition in facial
expressions
CANTABa (ERT) www.cambridgecognition.com/
tests/emotion-recognition-task-
ert
Rapid Visual information
Processing
Sustained attention CANTABa (RVP) www.cambridgecognition.com/
tests/rapid-visual-information-
processing-rvp
Information Sampling Test Reflection impulsivity and
decision-making
CANTABa (IST) www.cambridgecognition.com/
tests/information-sampling-
task-ist
Stop Signal Task Response inhibition CANTABa (SST) www.cambridgecognition.com/
tests/stop-signal-task-sst
TASIT, Part A2 Social
Inference (minimal))
Social perception The Awareness of Social Inference Test [59]
B-SIT Olfactory function Brief Smell Identification Test [60]
Word Selective Reminding
task
Verbal memory function Test of Memory and Learning 2nd ed. [60]
Observations
TOF (age 12–18 years) Observed behavior and emotions
during test situation
Test Observation Form [63]
Questionnaires
BRIEF (age 12–17) BRIEF-A
(age 18+)
Executive functions in daily life Behavior Rating Inventory of Executive
Function
[75, 76]
ABAS-II Adaptive functioning The Adaptive Behavior Assessment
System-Second Edition
[77]
SRS (age 12–18 years) Social impairments, social awareness,
social information processing, capacity
for reciprocal social communication,
social anxiety/avoidance, autistic
preoccupations and traits
Social Responsiveness ScaleTM [78]
ADHD-RS (age 12–18 years) Symptoms of ADHD and conduct
disorders
Attention Deficit Hyperactive Disorder
rating scale
[79]
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Each of the recruited 22q11 deletion carriers were
matched by gender and age with a non-related control sub-
ject who was randomly recruited either through (a) the Da-
nish National Health Registers and contacted by letter, (b)
public online postings at http://www.forsogsperson.dk/, or
(c) among children of unpaid voluntary blood-donors who
participate in the Danish Blood Donor Study [51]. Upon
blood donation the parent (a blood donor) received a leaflet
and verbal information on the project. The actual recruit-
ment process was initiated only if the parent subsequently
returned a letter of interest.
Inclusion criteria
All subjects had to be at least 12 years old. Cases should
have a clinically genetic verified 22q11 deletion based on
standard clinical cytogenetic methods (Fluorescence In Situ
Hybridization, Multiplex Ligation-dependent Probe Amplifi-
cation, or array - Comparative Genomic Hybridization), and
subsequent confirmation. Cases had a deletion within the 3-
mega base region that defines the 22q11 deletion syndrome
at chromosome 22q11.2. Control subjects had to be unre-
lated to participating case subjects and not carry the 22q11
deletion. First-degree family members in families where the
22q11 deletion is segregating (parents and full siblings) were
also included if they were over 18 years of age whereas sib-
lings, carriers of the 22q11 deletion, were included if they
were over 12 years.
Exclusion criteria
Cases should not have a deletion outside the classical 3-
mega base region that defines the 22q11 deletion and
should not have a diagnosis of schizophrenia or any other
psychotic illnesses. Control subjects should not have a diag-
nosis of a) schizophrenia, schizotypal and delusional disor-
ders (ICD10 DF20-29); b) bipolar disorder (ICD10 DF30-
31); c) depression (ICD DF32-33) except for a past episode
of mild or moderate depression (ICD10 DF 32.0 or 32.1); d)
substance abuse; or e) have a first degree relative with a
psychotic illness. Control subjects should not be family
related to a case. Subjects having embodied metal frag-
ments (i.e. acquired metal implants from surgery or had a
metal brace for tooth corrections), were pregnant, or suf-
fered from severe claustrophobia were not recruited for the
MRI and fMRI sub-studies.
Ethical considerations
The study was approved by the Regional Ethical Committee
of Copenhagen, Denmark (project id: H-3-2012-136) and
the Danish Data protection Agency (project id: 2007-58-
0015). Access to data follows the statutory criteria given by
the Danish Personal Data Protection Act governed by the
Danish Data Protection Agency. Project data can be
provided through personal contact to the corresponding au-
thor. All participants went through a verbal and written in-
formed consent process. Participants under the age of 18
provided a verbal assent while their parent’s completed writ-
ten consent.
Participants
Of the 244 identified Danish 22q11 deletion carriers 136
where above the age of 12, alive, and without a
schizophrenia-form disorder. Of these we were able to con-
tact 69. In total 44 cases and 48 controls consented to par-
ticipate. The characteristics of recruited subjects are shown
in Table 2. The birth year distribution of the 44 22q11 dele-
tion carriers is depicted in blue in Fig. 1. A total of five
parent-offspring pairs for which the 22q11 deletion is trans-
mitted from a parent to the child are among the recruited
subjects.
Examinations
Upon inclusion all participants were evaluated using a pre-
defined protocol that assesses psychopathology and cogni-
tive functions in two separate sessions and include a set of
self-reporting questionnaires. Each participant was invited
to participate in EEG and structural and functional sub-
studies. Experienced physicians and trained psychometri-
cians conducted the psychiatric assessments and cognitive
testing during home visits or at the Danish Research Center
for Magnetic Resonance (DRCMR) at Hvidovre Hospital,
Copenhagen, Denmark. EEG and MR examinations were
conducted by trained researchers at the DRCMR. The
examination of all participants has been finalized, data has
been curated and data analyses are initiated.
Genetic assessment
All participants were screened for the presence of the
22q11 deletion using saliva samples collected after comple-
tion of the cognitive test session and on dried blood spot
samples obtained from the Danish Newborn Screening
Biobank [52], which contains the neonatal blood spots,
Table 1 The behavioral and cognitive test battery (Continued)
SCQ (lifetime version)
(W-381B)
Communication skills and social
functioning
Social Communication Questionnaire
lifetime form
[80, 81]
Edinburgh handedness
inventory
Handedness Edinburgh handedness inventory [66]
aCANTAB Cambridge Neuropsychological Test Automated Battery
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routinely obtained shortly after birth of all Danes since
1982.
DNA was purified using standard protocols and the
presence or absence of a deletion within the three mega
base region that defines the common 22q11.2 deletion were
obtained from Single-Nucleotide Polymorphism (SNP)
array analyses using the HumanOmniExpressExome Bead-
Chip (Illumina, Inc.).
Psychopathology and cognitive protocol
Prior to assessment each participant was carefully informed
on the course and procedures for the session. The protocol
included tests for the assessment of current state psycho-
pathology, intellectual functioning, and specific social- and
neurocognitive functions using; the Mini International
Neuropsychiatric Interview [53] or Mini International
Neuropsychiatric Interview for Children and Adolescents
[54] and the Structured Interview for Prodromal Syn-
dromes [55], the Reynolds Intellectual Screening Test [56],
the Coding and Letter-Number Sequencing sub-tests from
the fourth edition of the Wechsler Intelligence Scale
[57, 58], the Awareness of Social Inference Test, Part A2
Social Inference (minimal) [59], the Brief Smell Identifica-
tion Test [60], the Word Selective Reminding task from the
second edition of Test of Memory and Learning [61], and
the Tests for Spatial Working Memory, Intra-Extra Dimen-
sional set shift, Reaction Time, Emotion Recognition Task,
Rapid Visual Information Processing, Information Sam-
pling Test and Stop Signal Task from the Cambridge
Neuropsychological Test Automated Battery [62] (see
Table 1). All interviews and tests were applied in the same
order using a highly standardized procedure.
The consulting psychometrician immediately filled out
the standardized Test Observation Form [63] for each
participant age 12–21 to obtain a measure of observed be-
havior and emotions during the cognitive test situation.
Adult participants were also asked to fill out a set of self-
reported questionnaires or where appropriately assisted by
their nearest caretaker. Finally, parents of participants
under the age of 18 were asked to complete a set of parent-
response forms for their children (See Table 1).
Functional brain mapping protocols
Functional brain mapping consisted of separate EEG and
fMRI measurements during two types of auditory roving
MMN paradigms [64] in order to study the underlying
neural network of 22q11 deletion carriers compared to con-
trol subjects. In addition, the EEG protocol included an
auditory steady-state gamma entrainment paradigm to
study cortical integration of information. This paradigm al-
lows to test whether 22q11 deletion carriers show a
reduced entrainment of gamma band activity, similar to pa-
tients with schizophrenia [65].
The EEG and fMRI examinations were run in two separ-
ate sessions on two different days. Prior to testing each par-
ticipant was interviewed about their well-being during the
last 24 h (i.e. hours of sleep, intake of caffeine containing
Table 2 Demography and prevalence of previous and current mental disorder of the case–control sample recruited for the
functional studies and the non-recruited 22q11 deletion carriers
Recruited controls (n = 48) Recruited 22q11 carriers (n = 44) Non-recruited 22q11 carriers (n = 92)
Mean age (age span) 20.3 (12–48) 20.3 (12–48) 22.6(12–54)
Male:female ratio 28: 20 25:19 41:51
Caucasian ancestry a 47 44 n.a.
3 megabase deletion (%) 0 (0 %) 41 (93 %) n.a.
Segregation (%) 0 (0 %) 5 (11 %) 4 (4 %)
RIST general intelligence (S.D)b 107.7 (11.1) 78.9 (17.4) n.a.
Diagnoses % (current state disorder)c
Alcohol and psychoactive substance dependence 0 (0) 0(0) 1.6(n.a.)
Schizophrenia Spectrum disorders 0 (0) 0(0) 0 (n.a.)
Affective disorders 0 (0) 7 (4.5) 4.3(n.a.)
Anxiety and Fobia (1) 9.1 11 (18.2) 8.7(n.a)
Anorexia 0(0) 0(0) 0 (n.a)
Intellectual disability 0 (n.a) 34 (n.a) 29.3(n.a)
Autism 0(n.a) 11 (n.a) 6.5(n.a)
ADHD 0 (0) 9 (11.4) 8.7(n.a)
n.a not assessed
aOne control subject had Asian ancestry
bIQ scores are derived from the Reynolds Intellectual Screening Test (RIST) using pre-access to an updated raw- to T-score table kindly provided by the publisher
(in submission)
cPercentages in () represents current diagnostics obtained from the M.I.N.I or M.I.N.I-kid diagnostic interviews
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beverages and medication), tested for handedness using the
Edinburgh handedness inventory [66] and subjected to two
hearing tests. A standardized hearing test was used to test
for the ability to detect different frequencies using an
Oscilla USB-310 Tablet screening audiometer. A custom
made psychophysical test assessed subjects’ subjective
perception of tones between 30db and 90 db using 1–10
point likert scale (1 – cannot hear anything, 10 very loud).
Mismatch negativity paradigm
In both EEG and fMRI, we used identical MMN paradigms,
which are referred to as “roving” MMN paradigms [64]. In
these roving MMN paradigms a sequence of repeated audi-
tory standard tones was presented followed by an oddball
that was randomly introduced. The oddball then became
the new standard that again was followed by a new oddball
stimuli [64]. We applied two different roving MMN para-
digms: a “single” and a “multiplex” paradigm. In the single
MMN paradigm the oddball occurred in only one auditory
feature, namely frequency (pitch). Here we used either
1000Hz or 1200Hz while tones were played for 50 ms with
an inter stimulus interval of 450 ms. In the multiplex
MMN paradigm, an oddball occurred in frequency (Hz)
and duration (ms), independently from each other. Here
again, pitch oddballs occurred in either 1000Hz or 1200Hz
while duration oddballs were defined as tones being played
for either 50 or 100 ms with an inter stimulus interval of
450 or 400 ms respectively. Each of the MMN paradigms
was applied for a total of 12 min in the fMRI setting and
for 15 min in the EEG set-up.
Gamma entrainment paradigm
In the EEG session, subjects were presented with an audi-
tory gamma entrainment paradigm, with sequences of
40Hz click trains. Each sequence of stimulation was of 1-
second duration, followed by a pause of 2 sec, and thus a
stimulus onset asynchrony of 3 sec. The clicks were distrib-
uted regularly with a constant distance at a rate of 40 clicks
per second each of 1 ms duration. As a control condition
clicks were presented at a rate of 40Hz, but with the clicks
spaced irregularly over the 1-second stimulation period,
hence the control stimulus had the same physical property
and only differed in how the sequence was presented,
meaning that locale frequencies could deviate from 40Hz.
The irregular sequence was kept constant within a session
for a specific subject but differed across subjects. The two
conditions were recorded during two independent blocks
of 6 min each.
Magnetic resonance imaging of the brain
Prior to scanning, subjects were carefully instructed about
the experimental procedures and had to perform a test trial
of the MMN paradigms to get accustomed to stimuli and
task. Subjects were scanned on a Siemens Verio 3T scanner
(Siemens, Erlangen, Germany) in two consecutive sessions
of each 45 min with a 15 min break in between. Brain scans
in the first session were acquired with a 12-channel
phased-array head coil, and consisted of a 3D T2-weighted,
sagittal, turbo spin echo sequence of the whole brain (TR 1
= 5000 ms; TE = 395 ms; FOV= 250 × 250; matrix = 256 ×
256; GRAPPA: factor = 2; lines = 24, 176 sagittal slices with
no gap, 1 mm3 voxels), followed by 2 T2*-weighted echo
planar imaging fMRI scans for the two MMN paradigms
(TR = 2150 ms, TE = 26 ms, flip angle = 78 °, matrix = 64 ×
64; FOV= 192 × 192; 42 axial slices with 0.4 mm gap,
3 mm3 voxels; 345 images, 12 min). The initial four images
of each fMRI scanning session were discarded to allow for
equilibration of T1 signal. Additionally, we acquired two
reference scans with the same sequences parameters as in
the fMRI acquisition but with opposite phase encoding di-
rections in order to correct for geometric distortions due to
B0 magnetic field inhomogeneities [67].
After subjects were offered a break outside of the scanner
bore, scanning was continued with a 32-channel coil. In the
second session, we acquired a high-resolution three-
dimensional T1-weighted, sagittal, magnetization-prepared
rapid gradient echo (MPRAGE) anatomical scan of the
whole brain (TR = 1900 ms, TI = 900 ms, TE = 2.32 ms, flip
angle = 9°, matrix = 256 × 256, FOV= 230 × 230, 224 sagittal
slices with no gap, 0.9 mm3 voxels), followed by whole-
brain diffusion weighted imaging. Diffusion weighted im-
aging used a twice-refocused balanced spin echo sequence
that minimized eddy current distortions [68] with ten non-
diffusion-weighted images (b = 0) and 61 diffusion-
weighted images (b = 1500 s/mm2) encoded along 61 inde-
pendent collinear diffusion gradient orientations [68] (TR
= 11,440 ms; TE = 89 ms; FOV= 220 × 220; matrix = 96 ×
96; GRAPPA: factor = 2; lines = 24; 61 axial slices with no
gap; 2.3 mm3 voxels). Additionally, we acquired two refer-
ence scans with the same sequences parameters as in the
diffusion-weighted images acquisition but with opposite
phase encoding directions in order to correct for geomet-
ric distortions due to B0 magnetic field inhomogeneities.
Finally, we obtained 10 min resting-state fMRI (279 im-
ages), followed by two reference scans with opposite phase
encoding directions using the same parameters as the se-
quences used during the MMN paradigms. During the en-
tire time of scanning, subjects were shown a silent movie
with underwater scenery free from any sudden or salient
visual events in order to control for attentional load be-
tween subjects.
Electroencephalography
EEG data were recorded using a 128 channel ActiveTwo
Biosemi System, with a sampling frequency of 4096Hz.
Electrooculography and respiration pulse were recorded
using external electrodes. Stimuli were delivered binaurally
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via insert-earphones (E-A-RTONE 3A) using the Cogent
2000 toolbox [69], running in Matlab.
Prior to the session, subjects were carefully instructed
about the experimental procedures, and were presented
with a couple of tones to make them comfortable with the
stimuli. The EEG session was divided into five parts with a
break in between each; part 1) single roving MMN, lasting
15 min, part 2) gamma entrainment paradigm lasting
6 min, part 3) irregular gamma entrainment lasting 6 min,
part 4) resting state with eyes open lasting 6 min, and
finally part 5) multiplex roving MMN lasting 15 min,
resulting in a total time of 48 min excluding breaks. During
the two roving MMN paradigms subjects were shown the
same silent movie as in the scanning session. For the two
gamma entrainment paradigms as well as the resting state
part, subjects were asked to fixate on a fixation cross pre-
sented on a screen in front of them.
Power considerations
Studies of genetic high-risk individuals are limited by the
mutation and testing rate. However, we optimized the
power for this study by investigating the most frequent
mutation in humans. Although the 22q11 deletion sample
size in the current study is limited we are able to utilize the
Danish health registries to inform on how the recruited
sample compares to the known 22q11 population as a
whole. As depicted in Fig. 1 the sample that is recruited for
the functional studies has a birth year distribution that
resembles that of the entire Danish 22q11 population born
before 2001, which reflects our random recruitment strat-
egy. Likewise the diagnostic profile based on health registry
information of the recruited 22q11 deletion carriers does
not differ significantly (nominal p values >0.05) from that
of the non-recruited subgroup of Danish 22q11 deletion
carriers, who fulfill the same inclusion criteria as we applied
to the recruited sample (12 years of age or older, alive and
without schizophrenia (see Table 2, Fig. 1). Furthermore,
we also take familial mental health issues into consider-
ation. With the access to the Danish health registers we
therefore have the ability to generalize findings from our
sub-group of recruited individuals to the finite national case
population. This is a unique and worldwide-unmatched
possibility that we have in Denmark.
Discussion
There is emerging evidence that early intervention can im-
prove treatment outcome and reduce transition into psych-
osis and thus prevent some individuals from getting ill [1].
However, the challenge in psychiatry is to identify people at
high risk of becoming ill and the limited treatment options.
We have established a national initiative to study the
high-risk 22q11 deletion. In Denmark the majority of the
22q11 deletion carriers are known from an early age and
therefore we can study them longitudinally from before a
mental disorder sets in. With our initiative we are currently
addressing mental health, cognitive performance and
neurophysiological features among Danish 22q11 deletion
carriers. This enables us to obtain more accurate informa-
tion on comorbidity factors and about prodromal signs and
premorbid phenotypes of psychosis and about the morbid
presentation of ADHD and autism.
Perspectives for future studies by the Danish 22q11
initiative
We trust that our initiative will grow into more extended
projects where we can map molecular imprints of the
22q11 deletion and integrate this information with the data
that we are currently collecting to inform on the pathogen-
esis of the neurodevelopmental disorders that associate
with the 22q11 deletion.
Since access to relevant biological tissues is limited in
humans we will turn to studies in an orthologous 22q11 de-
letion mouse model that has been generated within the
22q11 Initiative for translational cross species studies. It has
been possible since the chromosome 22q11 region is highly
conserved between man and mice [70]. Many of the traits
that we have measured in the human subjects for the
current study are currently being followed up in mice.
Studies in mice also allow for more detailed and interven-
tional studies than possible in humans. Therefore, mouse
studies can map deficits across multiple levels from altered
behavior, anatomical and physiological changes to molecu-
lar disturbances.
We will extend the molecular analyses of the human
22q11 deletion carriers that we have recruited for the
current study. Our initial genetic screening for the 22q11
deletion is based on saliva samples and dried neonatal
blood spots retrieved from the Danish Neonatal Screening
Biobank [52]. The neonatal blood spot samples have proven
well suited for extended next-generation sequencing and
for metabolomic studies currently ongoing [71]. We will
use these blood samples to perform extended genetic
analysis to inform on additional genetic components (e.g.
additional copy number variants, point mutations at the
non-deleted 22q11 allele or elsewhere in the genome,
imprinting etc.) that may contribute to the observed pheno-
type in our recruited subjects or the entire sample of
known 22q11 deletion carriers in Denmark. Furthermore,
the neonatal bloodspot samples are also suitable for more
extended molecular profiling [72]. This opens up the possi-
bility to provide information on the impact on mental
health of early environmental exposures during prenatal
development.
Early detection and enhanced treatment efficacy is
required for mental health care improvements. Identifica-
tion of predictive premorbid signs in 22q11 deletion car-
riers that can be applied by early detection teams may alter
current clinical practice from treatment of manifest mental
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illness into targeted early interventions aimed for people at
risk. These early interventions may also be applicable to
symptomatic or genetic subjects at risk without known
etiology. New insights into the biological disease mecha-
nisms mandatory for novel drug developments, can im-
prove the efficacy of the pharmacological interventions to
prevent or delay the onset of mental illness not only for
22q11 deletion carriers but also for at-risk subjects with-
out known etiology.
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